Unlock instant, AI-driven research and patent intelligence for your innovation.

Tamoxifen derivatives for treatment of neoplastic diseases, especially with high HER2 protein level

A technology of tamoxifen and derivatives, which can be used in antitumor drugs, compounds of Group 5/15 elements of the periodic table, organic chemistry, etc., and can solve problems such as secondary toxicity

Active Publication Date: 2016-03-30
SMART BRAIN +3
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The currently introduced drug lapatinib (lapatinib) that inhibits receptor tyrosine kinases has also been greatly challenged (EwerMS, EwerSM. Cardiotoxicity of anticancer treatments: what the cardiologist needs stoknow. NatRevCardiol2010; 6:485-493. AhnER et al Istheimprovedefficacyoftrastuzumabandlapatinibcombinationworththeadedtoxicity?BreastCancer2012;6:191-207.)
A problem in this context is that lapatinib, which is not a specific HER2 inhibitor, can also inhibit other receptor tyrosine kinases and cause secondary toxicity, and is also predictive of resistance to this treatment. Sexual production (WetterskogD et al. Identification of novel determinants of resistance to lapatinibin ERBB2-amplified cancers. Oncogene 2013; 1-11)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tamoxifen derivatives for treatment of neoplastic diseases, especially with high HER2 protein level
  • Tamoxifen derivatives for treatment of neoplastic diseases, especially with high HER2 protein level
  • Tamoxifen derivatives for treatment of neoplastic diseases, especially with high HER2 protein level

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0088] Dissolve (9-((tert-butyldimethylsilyl)oxy)nonyl)triphenylphosphonium bromide (634 mg, 1.057 mmol) in anhydrous tetrahydrofuran (THF) (6 ml) and Atmosphere covered and cooled to -78°C. Under argon atmosphere, butyllithium (1.2 ml, 0.9 MTHF solution) was slowly added dropwise to the reaction mixture. The solution was allowed to warm to 0°C, the color changed to deep red, cooled to -78°C again and a solution of the aldehyde of formula III (160mg, 0.430mmol) in anhydrous THF (3ml) was added dropwise. The reaction mixture was then allowed to warm to laboratory temperature and stirred under argon atmosphere for 16 hours. The progress of the reaction was monitored by thin layer chromatography (TLC) in chloroform-methanol mixture (10:1). Then, a saturated solution of ammonium chloride and water was added to the reaction mixture and extracted with ethyl acetate. The ethyl acetate layer was washed with brine and dried over magnesium sulfate. The solution was filtered and conc...

Embodiment 2

[0093] The silylated derivative of formula 4 (147mg, 2.240mmol) was dissolved in THF (5ml), and then covered with an argon atmosphere and under stirring at a temperature of 0°C, tetrabutylammonium fluoride was added dropwise (TBAF) (260 μl, 1M THF solution). The reaction mixture was then allowed to warm to laboratory temperature and stirred for an additional 6 hours. The progress of the reaction was monitored by TLC in a chloroform-methanol mixture (10:1). Then, water was added and the mixture was extracted with ethyl acetate. The ethyl acetate layer was washed with saturated soda solution and brine and dried over magnesium sulfate. The drying agent was filtered and the solution was concentrated under reduced pressure. The concentrate was purified by column chromatography on silica gel using a chloroform / methanol system (0 to 10% methanol gradient) to afford 115 mg (96% yield) of the desired enol of formula 5.

[0094]

[0095] 1 HNMR (500MHz, cdcl3) δ7.43-7.14 (m, 5H)...

Embodiment 3

[0097] The enol derivative of Formula 5 (115 mg, 0.231 mmol) was dissolved in absolute ethanol (6 ml) and covered with an argon atmosphere. 10% Pd / C (10 mg) was added to the mixture and the flask with the reaction suspension was evacuated and covered with a hydrogen atmosphere several times. The reaction mixture was then stirred at laboratory temperature under hydrogen atmosphere for 24 hours. The progress of the reaction was monitored by TLC in a chloroform-methanol mixture (10:1). The mixture was filtered through a pad of celite and rinsed several times with ethanol. Ethanol was evaporated to give 101 mg (87% yield) of the desired alcohol of formula 6 which was used in the next step of the synthesis without any further purification.

[0098]

[0099] 1 HNMR (500MHz, cd3od) δ7.40-7.01 (m, 10H), 6.85 (d, J = 8.1, 2H), 6.68 (d, J = 8.1, 2H), 4.20 (s, 2H), 3.55 (t, J=6.4,2H),3.46(s,2H),2.89(s,6H),2.42(t,J=7.8,2H),1.57-1.48(m,2H),1.38-1.11(m,12H). ESIMS: 500.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The subject of the invention are new mitochondrially targeted E / Z isomers of aliphatic triphenylphosphonium derivatives of tamoxifen where the aliphatic chain is alkyl or alkenyl, and their corresponding tertiary amine salts and / or their mixture (MitoTAX). Alkyl triphenylphosphonium derivatives of tamoxifen have the general formula (I), where n=8 to 12 and where Z is selected from the group of organic salts or inorganic salts. Alkenyl triphenylphosphonium derivatives of tamoxifen have the general formula IA, where n = 6 to 10 and where Z has the above mentioned meaning. These compounds are applicable for the treatment of neoplastic disease, especially those with high HER2 protein levels. The drug for the treatment of neoplastic diseases according to the invention contains at least one E / Z isomer of aliphatic triphenylphosphonium derivatives of tamoxifen of the general formula (I) and / or IA or their corresponding salts of tertiary amine.

Description

technical field [0001] The present invention relates to novel mitochondria-targeted tamoxifen derivatives for the treatment of neoplastic diseases, especially tumors with high HER2 (human epidermal growth factor receptor 2) protein levels, which affect spontaneous cell division and tumor growth . Background technique [0002] Recent advances in molecular medicine have led to some improvements in the diagnosis and treatment of neoplastic diseases. Despite partial success, these pathologies remain a considerable challenge. For certain types of cancer, current therapies fail in some cases for a variety of reasons. On the one hand, this is the inherent resistance of tumor cells with their ability to constantly mutate and escape treatment, and on the other hand, it is also the heterogeneity of the tumor environment (HanahanD, WeinbergRA. Hallmarks of cancer: thenextgeneration. Cell2011;144:646-674) . Tumors of the same type have been shown to be highly variable for individual...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07F9/54A61P35/04A61K31/662
CPCC07F9/5442C07F9/5449C09B23/0008C09B23/141C09B69/001C09B69/008C09B23/0025C07F9/5456A61P35/00A61P35/02A61P35/04A61P43/00
Inventor 伊里·纽齐尔J·什图尔萨L·维尔纳
Owner SMART BRAIN